Today: 30 June 2026
DroneShield stock to watch after JPMorgan crosses 5% line; ASX:DRO ends week above A$4
10 January 2026
2 mins read

DroneShield stock to watch after JPMorgan crosses 5% line; ASX:DRO ends week above A$4

Sydney, Jan 10, 2026, 17:48 AEDT — Market closed

  • JPMorgan Chase & Co. disclosed a 5.09% holding in DroneShield in a Jan. 9 filing
  • DroneShield shares last closed up 4.4% at A$4.02; ASX reopens Monday
  • Focus turns to Q1 deliveries and cash receipts, ahead of February audited results

DroneShield Limited shares head into Monday’s trade in focus after a filing showed JPMorgan Chase & Co. and its affiliates had become a substantial holder in the Australian counter-drone systems maker. The U.S. bank group reported voting power of 5.09%, or about 46.5 million ordinary shares, after crossing the 5% threshold on Jan. 7, the notice dated Jan. 9 showed.

The disclosure lands as DroneShield tries to rebuild trust after a late-2025 slide tied to executive share sales and governance questions. “Investors have lost confidence in the stock after the directors, including the CEO and the chairman, sold every single share,” said Ron Shamgar, head of Australian equities at TAMIM Asset Management, in a November Reuters report.

DroneShield last closed up 4.4% at A$4.02 on Friday.

The filing came after the close, so it will be digested when the ASX reopens on Monday. Big bank names on a small-cap register can shift sentiment quickly, even when it’s not a straight “buy and hold” trade.

Australian rules require disclosure once an investor’s voting power tops 5%, and again when it moves by 1% or more. JPMorgan’s notice splits the holding across its trading, prime brokerage and stock-lending operations. A chunk of the position sits inside lending arrangements — shares temporarily loaned out and later returned — which can make stakes move around without a fresh view on the company’s outlook.

DroneShield has tried to pull attention back to orders, deliveries and cash. On Dec. 30 it said it had received an A$8.2 million order for a western military end-customer, with delivery expected by end-2025 or early Q1 2026 and payment expected in Q1; it also flagged about A$97.7 million in “locked in revenues” going into 2026.

Earlier in December, the company said it had received a A$49.6 million contract from a European reseller for a military end-customer, with deliveries and cash payments expected to be completed in Q1 2026.

Investors are now waiting for audited numbers and a cleaner read on cash conversion; in a December investor deck, DroneShield said its audited 2025 results are due in February as part of the annual report. Traders are likely to focus on cash receipts, margins and whether the late-2025 contract burst turns into cash on time in the March quarter.

But a “substantial holder” notice can reflect stock-lending and prime-brokerage flow as much as conviction, and positions can unwind fast if clients return borrowed stock. Any slip in delivery schedules or slower cash collection would test a stock that has shown it can move hard in both directions.

When the ASX reopens on Monday, Jan. 12, attention will be on whether DroneShield can hold the A$4 level and whether further 5% notices follow. After that, the next marker is the company’s February annual report and audited results.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Telix Pharmaceuticals (ASX:TLX) tops Australian growth stocks with large insider holdings
    June 30, 2026, 3:11 AM EDT. Telix Pharmaceuticals (ASX:TLX) is at the front of Australian growth stocks with high insider ownership, seen as a sign of management confidence. The biopharma group, focused on radiopharmaceuticals in cancer imaging and care, pulled in about US$803.8 million in sales, most of that coming from the U.S. The company's market cap stands at A$5.5 billion. Telix's cancer pipeline is broad, and its commercial footing is firm. Its key products, Illuccix and Gozellix, support 2026 revenue targets of US$950-970 million. There's still risk from regulatory and pricing pressure, but insiders remain aligned, and partnerships with United Imaging and Regeneron support the growth story. Also mentioned: Lindian Resources (ASX:LIN), market cap A$1.7 billion, which is pushing ahead on a rare earths project in Malawi. Both names show that shareholder interest tracks with insider backing.
Lululemon stock drops nearly 4% as tariff ruling stays unresolved — what to watch next
Previous Story

Lululemon stock drops nearly 4% as tariff ruling stays unresolved — what to watch next

Boeing stock climbs as FAA proposes new 737 inspections and investors eye delivery data
Next Story

Boeing stock climbs as FAA proposes new 737 inspections and investors eye delivery data

Go toTop